Blog

Adverse events analysis of Relugolix Orgovyx for prostate cancer based on the FDA Adverse Event Reporting System FAERS – Plos.org



Published on: 2024-10-22

Adverse events analysis of Relugolix Orgovyx for prostate cancer based on the FDA Adverse Event Reporting System FAERS - Plos.org - Image 1

Adverse events analysis of Relugolix Orgovyx for prostate cancer based on the FDA Adverse Event Reporting System FAERS - Plos.org - Image 2

Adverse events analysis of Relugolix Orgovyx for prostate cancer based on the FDA Adverse Event Reporting System FAERS - Plos.org - Image 3

Adverse events analysis of Relugolix Orgovyx for prostate cancer based on the FDA Adverse Event Reporting System FAERS - Plos.org - Image 4